These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

348 related items for PubMed ID: 27545848

  • 21. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.
    Rich P, Sigurgeirsson B, Thaci D, Ortonne JP, Paul C, Schopf RE, Morita A, Roseau K, Harfst E, Guettner A, Machacek M, Papavassilis C.
    Br J Dermatol; 2013 Feb; 168(2):402-11. PubMed ID: 23362969
    [Abstract] [Full Text] [Related]

  • 22. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
    Gordon KB, Duffin KC, Bissonnette R, Prinz JC, Wasfi Y, Li S, Shen YK, Szapary P, Randazzo B, Reich K.
    N Engl J Med; 2015 Jul 09; 373(2):136-44. PubMed ID: 26154787
    [Abstract] [Full Text] [Related]

  • 23. Long-term data on the proposed adalimumab biosimilar BCD-057 in patients with moderate to severe psoriasis: A randomized controlled trial.
    Samtsov AV, Bakulev AL, Khairutdinov VR, Kokhan MM, Korotaeva TV, Minullin IK, Vylegzhanina OA, Dubenskiy VV, Khalilov BV, Khotko AA, Zykova OS, Chumachenko IV, Lukyanov AM, Artemeva AV, Pukhtinskaia PP.
    PLoS One; 2022 Jul 09; 17(2):e0263214. PubMed ID: 35130291
    [Abstract] [Full Text] [Related]

  • 24. Anti-adalimumab antibodies in psoriasis: lack of clinical utility and laboratory evidence.
    Lombardi G, Perego S, Sansoni V, Diani M, Banfi G, Altomare G.
    BMJ Open; 2016 Dec 09; 6(12):e011941. PubMed ID: 27940624
    [Abstract] [Full Text] [Related]

  • 25. Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study.
    Gordon KB, Armstrong AW, Han C, Foley P, Song M, Wasfi Y, You Y, Shen YK, Reich K.
    J Eur Acad Dermatol Venereol; 2018 Nov 09; 32(11):1940-1949. PubMed ID: 29706008
    [Abstract] [Full Text] [Related]

  • 26. Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial.
    Elewski BE, Okun MM, Papp K, Baker CS, Crowley JJ, Guillet G, Sundaram M, Poulin Y, Gu Y, Geng Z, Williams DA, Rich PA.
    J Am Acad Dermatol; 2018 Jan 09; 78(1):90-99.e1. PubMed ID: 28993005
    [Abstract] [Full Text] [Related]

  • 27. A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study.
    Thaçi D, Ortonne JP, Chimenti S, Ghislain PD, Arenberger P, Kragballe K, Saurat JH, Khemis A, Sprøgel P, Esslinger HU, Unnebrink K, Kupper H.
    Br J Dermatol; 2010 Aug 09; 163(2):402-11. PubMed ID: 20377585
    [Abstract] [Full Text] [Related]

  • 28. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.
    Papoutsaki M, Chimenti MS, Costanzo A, Talamonti M, Zangrilli A, Giunta A, Bianchi L, Chimenti S.
    J Am Acad Dermatol; 2007 Aug 09; 57(2):269-75. PubMed ID: 17574299
    [Abstract] [Full Text] [Related]

  • 29. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).
    Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, Dooley LT, Reich K, PHOENIX 2 study investigators.
    Lancet; 2008 May 17; 371(9625):1675-84. PubMed ID: 18486740
    [Abstract] [Full Text] [Related]

  • 30. Treatment effect of adalimumab and infliximab in Japanese psoriasis patients: results in a single community-based hospital.
    Noda S, Mizuno K, Adachi M.
    J Dermatol; 2012 Mar 17; 39(3):265-8. PubMed ID: 22126280
    [Abstract] [Full Text] [Related]

  • 31. Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE.
    Ortonne JP, Chimenti S, Reich K, Gniadecki R, Sprøgel P, Unnebrink K, Kupper H, Goldblum O, Thaçi D.
    J Eur Acad Dermatol Venereol; 2011 Sep 17; 25(9):1012-20. PubMed ID: 21214631
    [Abstract] [Full Text] [Related]

  • 32. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).
    Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP, Unnebrink K, Kaul M, Camez A, CHAMPION Study Investigators.
    Br J Dermatol; 2008 Mar 17; 158(3):558-66. PubMed ID: 18047523
    [Abstract] [Full Text] [Related]

  • 33. Adalimumab treatment optimization for psoriasis: Results of a long-term phase 2/3 Japanese study.
    Asahina A, Ohtsuki M, Etoh T, Gu Y, Okun MM, Teixeira HD, Yamaguchi Y, Nakagawa H.
    J Dermatol; 2015 Nov 17; 42(11):1042-52. PubMed ID: 26118825
    [Abstract] [Full Text] [Related]

  • 34. Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study.
    Revicki DA, Menter A, Feldman S, Kimel M, Harnam N, Willian MK.
    Health Qual Life Outcomes; 2008 Oct 02; 6():75. PubMed ID: 18831744
    [Abstract] [Full Text] [Related]

  • 35. A multicenter open-label experience on the response of psoriasis to Adalimumab and effect of dose escalation in non-responders: the Aphrodite project.
    Vena GA, Galluccio A, De Simone C, Mastrandrea V, Buquicchio R, La Greca S, Dattola S, Puglisi Guerra A, Donato L, Cantoresi F, De Pità O, Pezza M, D Agostino M, Vernaci R, Miracapillo A, Valenti G, Cassano N.
    Int J Immunopathol Pharmacol; 2009 Oct 02; 22(1):227-33. PubMed ID: 19309570
    [Abstract] [Full Text] [Related]

  • 36. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study.
    Gordon KB, Langley RG, Leonardi C, Toth D, Menter MA, Kang S, Heffernan M, Miller B, Hamlin R, Lim L, Zhong J, Hoffman R, Okun MM.
    J Am Acad Dermatol; 2006 Oct 02; 55(4):598-606. PubMed ID: 17010738
    [Abstract] [Full Text] [Related]

  • 37. Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis.
    Ryan C, Sobell JM, Leonardi CL, Lynde CW, Karunaratne M, Valdecantos WC, Hendrickson BA.
    Am J Clin Dermatol; 2018 Jun 02; 19(3):437-447. PubMed ID: 29380251
    [Abstract] [Full Text] [Related]

  • 38. Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial.
    Thaçi D, Vender R, de Rie MA, Conrad C, Pariser DM, Strober B, Vanvoorden V, Wang M, Madden C, de Cuyper D, Kimball AB.
    Br J Dermatol; 2023 Jan 23; 188(1):22-31. PubMed ID: 36689515
    [Abstract] [Full Text] [Related]

  • 39. Cost per response for guselkumab versus adalimumab in the United States using data from a head-to-head trial in moderate-to-severe plaque psoriasis.
    Teeple A, Muser E.
    J Med Econ; 2019 Dec 23; 22(12):1268-1273. PubMed ID: 31199173
    [Abstract] [Full Text] [Related]

  • 40. Efficacy of adalimumab in the treatment of psoriasis: a retrospective study of 15 patients in daily practice.
    Sola-Ortigosa J, Sánchez-Regaña M, Umbert-Millet P.
    J Dermatolog Treat; 2012 Jun 23; 23(3):203-7. PubMed ID: 21787203
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.